Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

AVXL


Fundamental

Company: Anavex Life Sciences Corp
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: Micro
Index: RUT
P/E: -
EPS (ttm): -0.46
Insider Own: 3.12%
Shs Outstand: 92.67M
Perf Week: 11.81%
Market Cap: 280.80M
Forward P/E: -
EPS next Y: -0.55
Insider Trans: 0.00%
Shs Float: 89.78M
Perf Month: -7.06%
Enterprise Value: 149.05M
PEG: -
EPS next Q: -0.08
Inst Own: 43.31%
Short Float: 21.42%
Perf Quarter: -31.60%
Income: -39.95M
P/S: -
EPS this Y: 38.89%
Inst Trans: 1.55%
Short Ratio: 14.18
Perf Half Y: -12.43%
Sales: 0.00M
P/B: 2.22
EPS next Y Percentage: -66.67%
ROA: -31.08%
Short Interest: 19.23M
Perf YTD: -14.89%
Book/sh: 1.37
P/C: 2.13
EPS next 5Y: -
ROE: -33.63%
52W High: 13.99 -78.34%
Perf Year: -60.29%
Cash/sh: 1.42
P/FCF: -
EPS past 3/5Y: 4.47% -3.79%
ROIC: -31.55%
52W Low: 2.61 16.09%
Perf 3Y: -67.49%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 6.16%
Volatility M: 5.80%
Perf 5Y: -75.66%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: 15.81%
Oper. Margin: -
ATR (14): 0.18
Perf 10Y: -32.06%
Dividend Ex-Date: -
Quick Ratio: 20.87
Sales Y/Y TTM: -
Profit Margin: -
RSI (14): 48.99
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 20.87
EPS Q/Q: 55.32%
SMA20: 0.52%
Beta: 1.19
Target Price: 20.00
Payout: -
Debt/Eq: 0.00
Sales Q/Q: -
SMA50: -5.23%
Rel Volume: 0.97
Prev Close: 2.94
Employees: 34
LT Debt/Eq: 0.00
Earnings: May 07
SMA200: -44.91%
Avg Volume: 1.36M
Price: 3.03
IPO: Aug 02, 2006
Option/Short: Yes / Yes
EPS/Sales Surpr.: 6.54% -
Trades:
Volume: 1,313,124
Change: 3.06%

Technical:


Latest News:

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference neutral
ANVS AVXL LGVN

Summary: Annovis Bio Inc. will participate in the H.C. Wainwright 26th Annual Global Investment Conference with a company presentation by Dr. Maccecchini discussing recent advancements and strategic direction, followed by a panel discussion on innovative non-amyloid approaches in Alzheimer’s disease.

Full article
2024-09-05T13:33:22Z